Vaxart (VXRT) has shared an announcement. Vaxart, Inc. stockholders have given the green light for significant expansions to the company’s equity plans and an increase in authorized shares. This move, ...

VAXART ($VXRT) posted quarterly earnings results on Thursday, March 20th. The company reported earnings of -$0.05 per share, beating estimates of -$0.10 by $0.05. The ...

Oppenheimer initiated coverage on Vaxart Inc. (NASDAQ:VXRT), an American biotechnology company focused on the discovery, development, and commercialization of oral recombinant vaccines. The analyst’s ...

Vaxart Inc (NASDAQ:VXRT) shares are trading higher in Monday’s after-hours session after the company provided business and cash runway updates. What Happened: Vaxart, a clinical-stage biotechnology ...

Greetings. Welcome to the Vaxart Business Update and First Quarter 2025 Financial Results Conference Call. A question-and-answer session will follow management's opening remarks. Individual investors ...

Vaxart, Inc. is a clinical-stage biotechnology company, which engages in the development of oral recombinant vaccines based on its Vector-Adjuvant-Antigen Standardized Technology (VAAST) oral vaccine ...

Vaxart (NASDAQ:VXRT) just reported results for the first quarter of 2024. Vaxart reported earnings per share of -14 cents. This met the analyst estimate for EPS of -14 cents. The company reported ...

Vaxart (NASDAQ:VXRT) just reported results for the second quarter of 2024. Vaxart reported earnings per share of -9 cents. This was below the analyst estimate for EPS of -3 cents. The company reported ...